{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(4)"],"submitter":["Wood RA"],"pubmed_abstract":["<h4>Background</h4>Food allergy is common and causes substantial morbidity and even mortality. Safe and effective treatments for food allergy would therefore be highly desirable, especially for individuals with multiple food allergies.<h4>Objectives</h4>Our aim was to describe a phase 3 study on treatment of patients with multiple food allergies with omalizumab.<h4>Methods</h4>The study was developed as a collaboration between the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Diseases, and 2 industry sponsors (Genentech and Novartis).<h4>Results</h4>The study is currently under way, enrolling participants from age 1 year to age 55 years who are allergic to peanut and at least 2 other foods (including milk, egg, wheat, cashew, hazelnut, and walnut). "],"journal":["The journal of allergy and clinical immunology. Global"],"pagination":["225-232"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10509974"],"repository":["biostudies-literature"],"pubmed_title":["Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)."],"pmcid":["PMC10509974"],"pubmed_authors":["Kim EH","OUtMATCH study team","Fogel RB","Kulis M","Kaufman D","Babineau DC","MacPhee M","Wood RA","Uddin A","Ligueros-Saylan M","Vickery BP","Chinthrajah RS","Hamrah S","Spergel JM","Jones SM","Poyser J","Bird JA","Davidson W","Rudman Spergel AK","Shreffler WG","Iqbal A","Umetsu DT","Veri M","Sicherer SH","Mudd K","Lussier S","Leung DYM","Long A","Togias A"],"additional_accession":[]},"is_claimable":false,"name":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).","description":"<h4>Background</h4>Food allergy is common and causes substantial morbidity and even mortality. Safe and effective treatments for food allergy would therefore be highly desirable, especially for individuals with multiple food allergies.<h4>Objectives</h4>Our aim was to describe a phase 3 study on treatment of patients with multiple food allergies with omalizumab.<h4>Methods</h4>The study was developed as a collaboration between the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Diseases, and 2 industry sponsors (Genentech and Novartis).<h4>Results</h4>The study is currently under way, enrolling participants from age 1 year to age 55 years who are allergic to peanut and at least 2 other foods (including milk, egg, wheat, cashew, hazelnut, and walnut). ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T15:24:43.242Z","creation":"2025-04-05T15:24:43.242Z"},"accession":"S-EPMC10509974","cross_references":{"pubmed":["37779534"],"doi":["10.1016/j.jacig.2022.05.006"]}}